Provectus Pharmaceuticals Inc. Release: PV-10's Systemic Tumor-Specific Immune Response is Subject of Research Article Published in PLOS ONE

Published: Jul 25, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announces that an article based on research conducted at the Moffitt Cancer Center with intralesional PV-10 has been published in PLOS ONE, an international, peer-reviewed, open-access, online publication. The article, entitled, “Intralesional Injection of Rose Bengal Induces a Systemic Tumor-Specific Immune Response in Murine Models of Melanoma and Breast Cancer,” was authored by Paul Toomey, M.D., Krithika Kodumudi, Ph.D., Amy Weber, Lisa Kuhn, Ellen Moore, Arnod A. Sarnaik, M.D. and Shari Pilon-Thomas, Ph.D., all researchers with Moffitt’s Immunology Program. The featured work resulted in part from a Provectus-sponsored research program led by Pilon-Thomas.

Help employers find you! Check out all the jobs and post your resume.

Back to news